Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nilius, A. M.
Right arrow Articles by Flamm, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nilius, A. M.
Right arrow Articles by Flamm, R. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 831-836
© 2002 The British Society for Antimicrobial Chemotherapy

Comparison of selection for mutants with reduced susceptibility to ABT-773, erythromycin and rifampicin in respiratory tract pathogens

Angela M. Nilius*, Dena M. Hensey-Rudloff, Megan A. Reimann and Robert K. Flamm

Infectious Diseases Research, Abbott Laboratories, Abbott Park, IL 60064-3537, USA

Received 10 September 2001; returned 13 November 2001; revised 16 January 2002; accepted 31 January 2002.

Attempts were made to select mutants on agar media containing the new ketolide ABT-773, erythromycin or rifampicin, at concentrations above the MICs, from Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae, including erythromycin-resistant strains. ABT-773 did not select for mutants in four strains, whereas in eight strains the frequencies at 72 h were <=10–9. ABT-773 MICs were 0.015–4 mg/L for mutants, except those selected from inducible Erm(A) S. aureus. Mutants selected on ABT-773 or erythromycin were cross-resistant to ABT-773, erythromycin and, sometimes, clindamycin. The susceptibility profiles indicate that different mutations were selected and that ABT-773 and erythromycin may interact with the ribosome differently.

* Corresponding author. Tel: +1-847-937-7706; Fax: +1-847-935-0400; E-mail: angela.nilius{at}abbott.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
E. Azoulay-Dupuis, J. Mohler, J. P. Bedos, C. Barau, and B. Fantin
Efficacy of Cethromycin, a New Ketolide, against Streptococcus pneumoniae Susceptible or Resistant to Erythromycin in a Murine Pneumonia Model.
Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3033 - 3038.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. H. Jorgensen, S. A. Crawford, M. L. McElmeel, and C. G. Whitney
Activities of Cethromycin and Telithromycin against Recent North American Isolates of Streptococcus pneumoniae
Antimicrob. Agents Chemother., February 1, 2004; 48(2): 605 - 607.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.